Measles (Rubeola) Resources for Health Care Providers
Measles cases are rising in the United States and globally.
Prompt recognition, reporting, and investigation of measles cases are important. You can help limit disease spread with vaccines and early case identification.
What's New
- Frequently Asked Questions about Infection Prevention and Measles
- Measles Contact Investigations in Hospitals and Health Care Systems (PDF)
- Webinar: Measles Update for NC Providers: Feb. 27, 2026 (YouTube)
- Providers should consider early vaccination for infants (6-11 months) in or visiting areas with sustained community transmission or exposure risk.
- People exposed to a confirmed case of measles may be eligible for post-exposure prophylaxis (PEP) if they do not have evidence of immunity.
For Local Health Departments
The MMR vaccine is the best way to protect against measles.
- Make sure patients are up to date on routine vaccination. Talk with parents about the importance of the vaccine.
- If a patient without evidence of immunity is exposed to measles, they may be eligible for post-exposure prophylaxis (PEP) right away.
- Early vaccination may be recommended for some infants:
- Before international travel or to an area of the U.S. where an outbreak is occurring, or
- When there is community transmission in their area of residence in NC.
CDC recommendations
- Dose 1: 12-15 months
- Dose 2: 4-6 years (before school entry)
Effectiveness
- One dose: 93% effective
- Two doses: ≥97% effective
Do not accept verbal reports of vaccination without written documentation.
Presumptive evidence of measles immunity includes:
- Written documentation of:
- One or more doses of a measles-containing vaccine administered on or after the first birthday for preschool-age children and adults not at high risk
- Two doses of a measles-containing vaccine, administered at least 28 days apart, for school-age children and adults at high risk, including college students, health care workers and international travelers
- Birth before 1957
- Laboratory evidence of immunity
- Laboratory confirmation of disease
Use the North Carolina Immunization Registry (NCIR) to access MMR coverage of your eligible patient population. One dose of MMR vaccine, or other presumptive immunity, is sufficient for most U.S. adults born in or after 1957.
Early MMR Vaccination for Infants (6-11 Months)
Early vaccination may be considered for
- Infants living in counties with sustained community transmission
- Infants in nearby areas with likely exposure risk
- Infants planning international travel
Areas with possible community transmission
- Buncombe County
- The Charlotte Metropolitan area, including these counties: Cabarrus, Gaston, Iredell, Lincoln, Mecklenburg, Rowan, Union
Travel recommendations
All U.S. residents 6 months and older without evidence of immunity who are planning to travel internationally or to U.S. areas with known outbreaks should get the MMR vaccine before departure.
| Age | Doses |
|---|---|
| Infants 6-11 months | One dose MMR before departure Infants who get the MMR vaccine before their first birthday should get two additional doses as part of the routine childhood immunization schedule, beginning at 12-15 months. |
| Children 12 months and older | Two doses of MMR, at least 28 days apart, before departure |
| Teens and adults without evidence of measles immunity | Two doses of MMR, at least 28 days apart, before departure |
Measles is highly contagious and can cause severe illness in infants:
- 1 in 5 are hospitalized
- 1 in 20 develop pneumonia
- 1 in 1,000 develop encephalitis
- 1 to 3 in 1,000 may die
Infants younger than 12 months are at highest risk for severe complications.1, 2
Early MMR vaccination (6-11 months) can reduce risk of disease and death during outbreaks.
- 1
Leung J, Munir NA, Mathis AD, et al. The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Postelimination Era, 2001-2022. Clinical Infectious Diseases. 2025;80(3):663-672.
- 2
Perry RT, Halsey NA. The clinical significance of measles: a review. Journal of Infectious Diseases. 2004;189 Suppl 1:S4-16. doi: 10.1086/377712.
- Pediatricians should weigh benefits of early protection vs. slightly lower immune response in younger infants.
- Efficacy concerns: Data suggest many infants may not derive high levels of protection from this early dose, possibly due to maternal antibodies blunting the immune response.3
- Because of this, the dose is "extra": This early dose does not count toward the primary series. The child will still require the standard two doses starting at or after 12 months of age.
- Long-term immunity: There is some evidence that children who receive an early dose may experience a more rapid decay of antibody titers later in life, potentially resulting in lower overall protection as adults.4, 5, 6
- There is no need for immune globulin (IG) post-exposure or home quarantine if infant has previously received one early MMR dose.
- MMR is preferred over IG for infants 6–11 months if given within 72 hours of exposure. If ≥72 hours post-exposure, IGIM/IVIG may be considered within 6 days of exposure. Infant would still need home quarantine.
- VFC MMR can be used for the early dose for VFC eligible infants.
- 3
Brinkman ID, de Wit J, Smits GP, et al. Early measles vaccination during an outbreak in the Netherlands: short-term and Long-term decreases in antibody responses among children vaccinated before 12 months of age. Journal of Infectious Diseases 2019;220(4):594–602.
- 4
Gans HA, Yasukawa LL, Sung P, et al. Measles humoral and cell-mediated immunity in children aged 5–10 years after primary measles immunization administered at 6 or 9 months of age. Journal of Infectious Disease 2013;207(4):574–82.
- 5
van der Staak M, Hulscher HI, Nicolaie AM, et al. Long-term Dynamics of Measles Virus–Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age. Clinical Infectious Diseases 2025;80(4):904-910
- 6
Vittrup DM, Jensen A, Sørensen JK, et al. Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants. EClinicalMedicine 2024;68:102421.
- Infants who receive early dose should be scheduled for:
- Routine Dose 1 at 12-15 months (at least 28 days after the early dose)
- Routine Dose 2 at 4-6 years
- Maintain clear documentation of all doses
Safety of the MMR Vaccine
- MMR is safe and effective; serious adverse events are rare.
- Reactions to the MMR vaccine can resemble measles disease. Common side effects include: mild fever, rash, sore arm.
- Febrile seizures are rare and not associated with long-term health effects.
Post-Exposure Prophylaxis (PEP)
People exposed to a confirmed case of measles may be eligible for post-exposure prophylaxis (PEP) if they do not have evidence of immunity.
Options
- MMR vaccine within 72 hours of exposure
- Immunoglobulin (IG) within six days of exposure.
IG is recommended for people at high risk of complications, including:
- Infants younger than 12 months*
- Pregnant women
- People who have compromised immune systems, regardless of vaccination status
*In a measles outbreak setting, infants 6-11 months can get MMR vaccine in lieu of IG if administered within 72 hours of exposure.
Don't administer MMR vaccine and IG at the same time. This practice invalidates the vaccine.
Identifying Cases and Infection Control
Consider the diagnosis of measles in anyone presenting with a febrile rash illness and compatible symptoms of cough, coryza, conjunctivitis and recent international travel or travel to a region reporting recent cases.
Diagnosis Resources
- Fever, Rash and Travel? Consider Measles (PDF)
- Think Measles: Clinician Job Aid (American Academy of Pediatrics) (PDF)
- REDBook Measles Guidance
Suspect measles? Call the state Communicable Disease Branch at 919-733-3419 (available 24/7) or your local health department to discuss lab testing and control measures.
Infection Control Frequently Asked Questions
Reduce exposures in health care settings as much as possible before and upon arrival of a patient with a known or suspected measles case. Prepare triage stations to rapidly identify patients with measles.
Measles Contact Investigations in Hospitals and Health Care Systems (PDF)
- Consider a screening process for your facility to identify patients with signs and symptoms of measles prior to arrival.
- Consider evaluating a patient with signs or symptoms of measles outside the clinic (e.g., in their car, outdoors) if the patient’s condition is suitable.
- For people with signs or symptoms of measles, provide instructions for arrival, including:
Which entrance to use
How to let staff know they have arrived
To wear a facemask in the facility (if possible)
- Post signs/posters in appropriate languages listing the signs and symptoms of measles and instruct individuals on what to do if they experience symptoms.
- Post signs/posters in appropriate languages about respiratory hygiene, cough etiquette, and hand hygiene at the facility entrance and in common areas (such as waiting areas, elevators, cafeterias).
- Provide hygiene supplies such as hand hygiene products, facemasks, tissues, etc.
- Instruct emergency services to notify the receiving facility/accepting physician in advance when transporting a patient with known or suspected measles.
When the patient arrives, the patient should be taken immediately to an airborne infection isolation room (AIIR), if available. If an AIIR is not available, place the patient in a private room that minimizes shared air space with other areas. Keep the door closed, have the patient wear a mask (if possible) and transfer the patient as soon as possible to a facility where an AIIR is available.
When transporting the patient through the facility, avoid busy hallways and large common spaces. Keep in mind that even a short time in shared air space could lead to possible exposures, and that anyone in that airspace when the patient passes through and in the next two hours, may be considered exposed. For more information, see "What is an exposure?"
Recommended respiratory protection is a respirator that is at least as protective as a fit-tested, NIOSH-certified, disposable N95 filtering facepiece respirator.
Those wearing surgical/procedural masks, KN95, etc. are not considered protected against measles.
In health care settings, people potentially exposed to measles include patients, visitors, and health care personnel who are not wearing recommended respiratory protection* (regardless of presumptive evidence of measles immunity status) who are:
- In a shared air space** with an infectious measles patient at the same time, or
- In a shared air space** vacated by an infectious measles patient within the prior 2 hours (or the period of time aligning with the CDC ACH Table).
This exposure definition includes any period of time in the space for either the infectious patient or the exposed people. While a mask minimizes the potential of transmission, a mask does not eliminate possible exposure.
Be prepared to do contact tracing, notify and administer post-exposure prophylaxis (PEP) if appropriate to anyone in your facility who is considered exposed.
For more information on health care exposure investigations, see Measles Contact Investigations in Hospitals and Health Care Systems (PDF).
For more information on PEP, see Measles Post-Exposure Prophylaxis (PEP) for Non-Symptomatic Susceptible Contacts (PDF).
*Recommended respiratory protection is a respirator that is at least as protective as a fit-tested, NIOSH-certified, disposable N95 filtering facepiece respirator.
**Different areas in larger spaces or rooms that share a common air handling system, such as a large emergency department with patient waiting, triage, HCP work areas, or multiple individual patient rooms that share a common unfiltered air source, are also shared airspaces.
After the patient leaves the space, the space should remain vacant up to 2 hours to allow for 99.9% of airborne-contaminant removal. For spaces with known rate of air changes per hour (ACH), this time may be decreased as directed by the CDC ACH Table.
Personnel responsible for maintaining the building's air handling system(s) should be consulted when assessing exposure risk between different rooms or areas of a facility, e.g., to identify where ventilation return air is recirculated (without passing through HEPA filtration). Different areas in larger spaces or rooms that share a common air handling system, such as a large emergency department with patient waiting, triage, HCP work areas, or multiple individual patient rooms that share a common unfiltered air source, are also shared airspaces.
Personnel who enter the room before the appropriate time for airborne-contaminant removal has passed should wear respiratory protection (i.e., a respirator) that is at least as protective as a fit-tested, NIOSH-certified disposable N95 filtering facepiece respirator.
Standard cleaning and disinfection procedures are adequate for measles virus environmental control in health care settings. Use an EPA-registered disinfectant, per manufacturer's instructions.
Personnel responsible for maintaining the building's air handling system(s) should be consulted when assessing exposure risk based on a facility’s air handling. When in doubt, reach out to device manufacturer to confirm function based on the specific model and installation.
Laboratory Testing
The most common methods for confirming measles infection are detection of:
- Measles virus RNA via polymerase chain reaction (PCR)
- Measles-specific IgM antibody
Testing through the State Laboratory of Public Health (SLPH)
SLPH offers measles PCR testing on-site and send-out testing, including serology and vaccine RNA testing for situations involving recent vaccination. Some commercial laboratories also offer testing for measles serology and PCR. In most circumstances, testing through SLPH is faster than commercial testing.
You must get prior approval to test through SLPH: Call the state Communicable Disease Branch at 919-733-3419 (available 24/7) or your local health department.
Treatment
There is no specific antiviral therapy available for treatment of measles. Patient management focuses on supportive care to relieve symptoms and treatment of complications such as pneumonia and secondary bacterial infections.
Vitamin A
Vitamin A does not prevent measles and is not a substitute for vaccination. Overuse of Vitamin A can lead to toxicity and cause nausea, vomiting, headache, fatigue, blurry vision, confusion and coma. It can also lead to damage to the liver, bones, central nervous system and skin.
NCDHHS recommends following guidance from the American Academy of Pediatrics and World Health Organization (WHO). Vitamin A may be administered to infants and children in the United States with measles under the supervision of a health care provider as part of supportive management. Vitamin A should be administered to all children with severe measles, such as those who are hospitalized.
Vitamin A for treatment of measles is administered as one dose immediately upon diagnosis and repeated the next day for a total of 2 doses. The recommended age-specific daily doses are:
- 50,000 IU for infants < 6 months
- 100,000 IU for infants 6 through 11 months
- 200,000 IU for children 12 months or older
- An additional (i.e., a third) age-specific dose of vitamin A should be given 2-6 weeks later to children with clinical signs and symptoms of vitamin A deficiency
More information: National Foundation for Infectious Diseases: Vitamin A for the Management of Measles in the United States (PDF)
More Resources
- Webinar: Measles Update for NC Providers: Feb. 27, 2026 (YouTube)
- Provider Memo: Consideration of early MMR vaccination in areas with measles transmission – 1/21/26
- Webinar: Measles Update for NC Providers (YouTube) – 1/9/26
- Webinar Slides: Measles Update for Clinical Providers – 7/9/25
- Provider Memo: Measles reporting, testing and vaccination – 6/26/25
More Information from the CDC
This page was last modified on 03/05/2026